

FY1920 Q1 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
18/LO/1013	244997	Craving Induction and Imagery-based Coping for Cocaine Use Disorder: Clinical Study	16/05/2018	30/07/2018	30/07/2018	10/09/2018	10/09/2018	10/09/2018	14/11/2018	Both
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	29/08/2018	17/08/2018	28/11/2017	21/08/2018	29/08/2018	29/08/2018		Neither
18/WA/0088	229419	A Phase 3, multicenter, randomized, double-blind, placebocontrolled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/ quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type.	25/04/2018	19/07/2018	26/04/2018	27/07/2018	02/08/2018	07/08/2018	18/01/2019	Neither
18/LO/0575	213457	A Validation Study of a computerized, Artificial Intelligence assisted cognitive assessment test compared to a widely used cognitive assessment test and specialist clinical diagnosis in patients with Alzheimer's Dementia and Mild Cognitive Impairment	15/06/2018	28/08/2018	16/05/2018	31/08/2018	04/09/2018	05/09/2018	25/09/2018	N/A

FY1920 Q1 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
18/EE/0151	244573	A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies (DELPHIA)	24/07/2018	19/09/2018	31/07/2018	19/09/2018	03/10/2018	03/10/2018	22/03/2019	Neither
18/LO/0287	235360	The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)	24/07/2018	25/07/2018	04/04/2018	03/08/2018	02/08/2018	31/08/2018		NHS Provider
18/LO/1001	246304	A Global PRospective, Multi-cEnter, ObServational post-markeT Study tO assess shoRt, mid and long-term Effectiveness and efficiency of VNS Therapy® as adjunctive therapy in real-world patlents with difficult to treat dEpression.	14/05/2018	04/09/2018	13/06/2018	05/09/2018	12/09/2018	13/09/2018	12/10/2018	N/A
18/LO/0731	246135	The Effects of Psilocybin on Cognitive Function in Healthy Participants	24/07/2018	25/07/2018	09/07/2018	03/08/2018	02/08/2018	06/08/2018	17/08/2018	N/A
18/LO/1722	249936	Telephone delivered Incentives for Encouraging adherence to Supervised methadone consumption: a feasibility study for a RCT of clinical and cost effectiveness (TIES)	05/09/2018	11/10/2018	12/11/2018	17/12/2018	17/12/2018	17/12/2018	14/01/2019	NHS Provider
18/LO/1683	241656	A randomised controlled feasibility study of food related computerised attention training for obesity versus active (mindfulness-based intervention MBI) and waiting list control (FOCUS)	04/09/2018	13/11/2018	13/11/2018	10/01/2019	10/01/2019	11/02/2019	20/03/2019	Both

FY1920 Q1 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
18/EM/0335	240188	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents with Autism Spectrum Disorders.	23/05/2018	12/11/2018						Neither
18/NW/0648	244170	ICARUS: An Investigation of Approach Bias Modification Training and Transcranial Direct Current Stimulation in Binge Eating Disorder	28/08/2018	07/11/2018	07/11/2018	12/03/2019	12/03/2019	12/03/2019	15/03/2019	Sponsor
18/LO/1634	244432	A pilot randomised controlled trial of Mindfulness Based Cognitive Therapy compared to Psychoeducation in adults with Attention-Deficit/Hyperactivity Disorder	29/08/2018	28/11/2018	28/11/2018	04/01/2019	04/01/2019	04/02/2019	21/02/2019	Neither
18/WS/0040	204214	A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia.	13/11/2018	11/12/2018	19/04/2018	12/12/2018	18/12/2018	19/12/2018	11/01/2019	N/A
18/LO/1890	245166	Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder: The R-LINK initiative	19/10/2018	09/01/2019	09/01/2019					Sponsor

FY1920 Q1 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
18/LO/02130	243427	Education and Employment focused Individual Placement and Support (IPS) within Early Intervention for Psychosis services: a feasibility study.	09/11/2018	18/01/2019	18/01/2019	02/04/2019	02/04/2019	02/04/2019	05/06/2019	Sponsor
19/LO/0199	256260	Internet-delivered Cognitive Therapy (iCT) for young people with Post-Traumatic Stress Disorder (PTSD): a development case series	04/01/2019	19/03/2019	19/03/2019	10/04/2019	10/04/2019	10/04/2019	02/05/2019	N/A
18/SC/0433	249835	A Phase I, randomized, placebo-controlled, open-label, three period crossover study to investigate the effect of darolutamide and enzalutamide on cerebral blood flow in healthy male volunteers.	10/09/2018	28/09/2018	19/09/2018	09/10/2018	16/10/2018	17/10/2018	24/10/2018	N/A
18/EM/0061	242931	A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness	15/05/2018	24/09/2018	01/05/2018	09/10/2018	17/10/2018	18/10/2018		Neither
18/NE/0248	246929	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, EFFICACY, AND SAFETY STUDY OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER WITH A 2-YEAR OPEN-LABEL EXTENSION	03/01/2019	21/03/2019	26/09/2018	22/03/2019	02/04/2019	05/04/2019		N/A

FY1920 Q1 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
19/LO/0054	252717	Targeting Inhibitory Control using Computerised Training among Patients with Bulimia Nervosa and Binge Eating Disorder	25/10/2018	06/02/2019	06/02/2019	29/05/2019	29/05/2019	29/05/2019	13/06/2019	Sponsor
19/LO/0483	255522	Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opioid Agonist/Partial Opioid Agonist Medication, with Personalised Psychosocial Intervention. The EXPO study.	26/02/2019	08/04/2019						Neither
19/LO/0622	232385	Optimising psychological treatment for Anxiety Disorders in Pregnancy: a feasibility study for a Trial of time-intensive CBT versus weekly CBT (ADEPT)	18/03/2019	13/04/2019	07/06/2019	20/06/2019	20/06/2019	20/06/2019		Neither
19/LO/0761	251923	Gut feeling: understanding the mechanisms underlying the antidepressant properties of probiotics (the PROMEX study)	04/04/2019	25/06/2019	25/06/2019	28/06/2019	28/06/2019	28/06/2019		N/A
19/SC/0084	254209	A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week treatment period in patients with schizophrenia	22/05/2019	31/05/2019	24/04/2019					N/A